[Federal Register Volume 76, Number 172 (Tuesday, September 6, 2011)]
[Notices]
[Page 55057]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-22701]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel; 
Amended Meeting Notice

AGENCY: Department of Defense (DoD), Assistant Secretary of Defense 
(Health Affairs).

ACTION: Amended Meeting Notice.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (5 U.S.C. Appendix 2) and the Government in the Sunshine Act of 
1976 (5 U.S.C. 552b), and 41 CFR 102-3.150 the Department of Defense 
announces a change to the previously announced meeting of the Uniform 
Formulary Beneficiary Advisory Panel. The meeting notice published in 
the August 16, 2011 edition of the Federal Register (76 FR 50720) is 
changed to reflect a change in the meeting agenda. The current agenda 
item, Multiple Sclerosis is replaced with Phosphodiesterase-5 
Inhibitors (PDE-5s). The Panel will review and comment on the 
Phosphodiesterase-5 Inhibitors, Non-Steroidal Anti-Inflammatory Drugs, 
Contraceptives, Designated Newly Approved Drugs in already reviewed 
classes and Pertinent Utilization Management Issues. All other aspects 
of the previously announced meeting agenda remain valid.

FOR FURTHER INFORMATION CONTACT: Mr. William H. Blanche, Alternate 
Designated Federal Officer, Uniform Formulary Beneficiary Advisory 
Panel, 2450 Stanley Road, Suite 208, Ft. Sam Houston, TX 78234-6102, 
Telephone: (210) 295-1271; Fax: (210) 295-2789, E-mail Address: 
[email protected].

    Dated: August 31, 2011.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2011-22701 Filed 9-2-11; 8:45 am]
BILLING CODE 5001-06-P